Clinical studies with B72. 3 in ovarian cancer and probe-guided tumor localization(411 views) Del Vecchio S, Camera L, Petrillo A, Esposito G, Frasci G, Iaffaioli RV, Bianco AR, Salvatore M
Nucl Med Biol (ISSN: 0883-2897, 0969-8051), 1991; 18(1): 85-87.
Affiliations: Nuclear Medicine Department, National Cancer Institute, Institute of Nuclear Medicine, Naples, Italy
Oncology Division, II School of Medicine, Naples, Italy
Istituto di Medicina Nucleare, II Facolta' Medicina/Chirurgia, Via S. Pansini 5, I-80131 Napoli, Italy
References: Aure, Hoeg, Kolstad, Clinical and histologic studies of ovarian carcinoma: long-term follow up of 990 cases (1971) J. Obstet. Gynecol., 37, pp. 1-1
Bast, Feeney, Lazarus, Nadler, Coluin, Knapp, Reactivity of a monoclonal antibody with human ovarian carcinoma (1981) Journal of Clinical Investigation, 68, pp. 1331-1333
Chatal, Fumoleau, Saccavini, Immunoscintigraphy of recurrences of gynecologic carcinomas (1987) J Nucl Med, 28, pp. 1807-1819
Epenetos, Shepherd, Britton, Radioimmunodiagnosis of ovarian cancer using 123I-labelled tumor associated monoclonal antibodies (1984) Cancer Detect Prev, 7, pp. 45-49
Granowska, Shepherd, Britton, Ovarian cancer: diagnosis using 123I- monoclonal antibody in comparison with surgical findings (1984) Nuclear Medicine Communications, 5, pp. 485-499
Granowska, Nimmon, Britton, Kinetic analysis and probability mapping applied to the detection of ovarian cancer by radioimmunoscintography (1988) J Nucl Med, 29, pp. 599-607
Griffiths, Parker, Fuller, Role of cytoreductive surgical treatment in the managment of advanced ovarian cancer (1979) Cancer Treat Rep, 63, pp. 235-238
Lastoria, D'Amico, Mansi, Giordano, Rossiello, Schlom, Pace, Salvatore, A prospective imaging study of 131I-B723 monoclonal antibody in patients with epithelial ovarian cancer preliminary report (1988) Nuclear Medicine Communications, 9, pp. 347-356
Louie, Ozols, Myers, Long term results of a cisplatin-containing combination chemotherapy regimen (Chex-UP) for the treatment of advanced ovarian carcinoma (1986) J Clin Oncol, 4, pp. 1579-1585
Ozols, Young, Chemotherapy of ovarian cancer (1984) Semin Oncol, 11, pp. 251-263
Pateisky, Philipp, Skodler, Radioimmunodetection in patients with suspected ovarian cancer (1985) J Nucl Med, 26, pp. 1369-1376
Pectasides, Pateniotis, Tzimis, Immunoscintigraphy with 131I-labeled monoclonal antibodies HMFG2 and HMFG1 F(ab′)2 versus abdominal CT scan in the detection of residual disease in ovarian cancer patients (1988) International Journal of Cancer, 3, pp. 83-88. , (Suppl.)
Thor, Ohuchi, Szpak, Johnston, Schlom, Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B723 (1986) Cancer Res, 46, pp. 3118-3124
Clinical studies with B72. 3 in ovarian cancer and probe-guided tumor localization
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(288 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote